Global Statistics Representing Gelatin Polypeptide Plasma Expanders Market Scenario
Gelatin polypeptide plasma expander comes with higher molecular weight that boosts the plasma volume by increasing the osmotic pressure. Currently, the market has two types of plasma expanders, namely colloid and crystalloids. Gelatin polypeptide plasma expander is a part of colloid expanders and can be used as an alternative to dextran, albumin, and other colloidal expanders. The therapeutic application of gelatin plasma expanders for hypovolemic shocks and other conditions involving blood loss is limited due to high level of endotoxin. However, numerous efforts are being taken to lower the endotoxin level from the base material, i.e. gelatin. Gelofusine and Haemaccel are the new generation gelatin expander popularly used across the U.K. As per the 6th National Audit Project of the Royal College of Anesthetists (NAP6), gelatin‐based products were the most frequently used colloid (1.7% of all fluid administrations) with starch or starch‐based products (0.2%) and albumin (0.1%). All the NHS hospitals have participated in NAP6.
Global gelatin polypeptide plasma expanders market was valued at USD 223.91 million in 2018, growing at a CAGR of 3.3% during the forecast period of 2019–2026.
For a better understanding of the global gelatin polypeptide plasma expanders market, we have segmented the market by type, source of gelatin and application.
By Application, the market is segmented into perioperative, extracorporeal circulation and dialysis. Perioperative is accounting for the largest market share and was valued at USD 134.6 million in 2018. This can be attributed to high number of surgeries and subsequent higher volume of blood loss, requiring plasma expanders to maintain the plasma volume.
Global gelatin polypeptide plasma expanders market by Americas, Asia Pacific, Europe, and the Middle East and Africa.
North America is dominating the market. Volume expander is an intravenous therapy used for treating blood disorders, blood loss, hypovolemia, pancreatitis, and trauma. The therapy is mainly used to treat patients who have been through a traumatic accident. Globally, the prevalence of road accidents is increasing at an alarming rate, and drunk driving is responsible for many of these accidents. Depending on the severity, the accident can cause injuries, life-long disability, and death. According to the WHO, around 20–50 million people are injured or disabled worldwide every year. In addition, road accidents are the third leading cause of death in the U.S. As per the Association for Safe International Road Travel Organization, approximately 2.35 million people are injured or disabled in the U.S. every year. Whereas, in Africa, over 650 people die every day, the UN.
Geriatric population is highly prone to home accidents. According to the UN, the global population aged 60 years was estimated to be over 962 million in 2017. In Europe, the number of elderly fatalities rose from 22% in 2010 to 27% in 2017, the EU. In 2016, Hospital admissions in England rose to a record high, i.e., 1.3 million admissions of patients aged between 65–69, the NHS.
Some of the prominent players in the market are B. Braun Medical Ltd, Abbott, Piramal Pharma, Fresenius Kabi AG, Sanofi, Serumwerk Bernburg AG, and Beacon Pharmaceuticals Ltd.
Gelatin Polypeptide Plasma Expanders Market Segmentation
By Source of Gelatin
Frequently Asked Questions (FAQs)